| Literature DB >> 31295962 |
Dong Kee Jang1, Jung Soo Lee2, Jun Kyu Lee1, Yeo Hyung Kim3.
Abstract
The aim of the current study was to examine the independent association of physical activity with nonalcoholic fatty liver disease (NAFLD) and aminotransferases while adjusting for obesity and diet. Cross-sectional data from 32,391 participants aged ≥ 20 years in the Korea National Health and Nutrition Examination Surveys (KNHANES) was analyzed by logistic regression models and general linear models. Physical activity was assessed from the questionnaire by health-enhancing physical activity (HEPA). The physical activity was negatively associated with NAFLD and lean NAFLD after adjustment for multiple factors with an odds ratio of 0.7 (95% CI, 0.6-0.8) and 0.5 (95% CI, 0.4-0.7) comparing the most active (HEPA active) and the least active (inactive) participants. Among the participants with NAFLD, physical activity also showed an independent negative association with alanine aminotransferase (ALT) levels but not with aspartate aminotransferase levels. These independent associations were not observed when comparing the minimally active and inactive participants except for the risk of lean NAFLD. Physical activity is independently associated with the degree of hepatocellular injury in patients with NAFLD as well as the risk of NAFLD and lean NAFLD in the general population. Sufficiently active physical activity greater than a minimally active level may be needed to lower the risk of NAFLD and ALT levels.Entities:
Keywords: exercise; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; physical activity; transaminases
Year: 2019 PMID: 31295962 PMCID: PMC6678247 DOI: 10.3390/jcm8071013
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flow diagram of participant inclusion and exclusion in the current study using data from the Korea National Health and Nutrition Examination Surveys (KNHANES IV, V, and VI). IPAQ-SF, International Physical Activity Questionnaire Short Form; NAFLD, nonalcoholic fatty liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus.
Characteristics of participants by physical activity level (n = 32,391).
| HEPA Active | Minimally Active | Inactive | ||
|---|---|---|---|---|
| Age (years) | 44.0 ± 0.3 | 44.9 ± 0.2 | 47.0 ± 0.2 | <0.001 |
| Male sex (%) | 56.8 (0.7) | 44.5 (0.6) | 41.1 (0.6) | <0.001 |
| BMI (kg/m2) | 23.8 ± 0.1 | 23.4 ± 0.0 | 23.6 ± 0.0 | <0.001 |
| Central obesity (%) | 21.6 (0.6) | 21.9 (0.5) | 24.4 (0.5) | <0.001 |
| Total calorie intake (kcal/day) | 2107.8 ± 15.1 | 1942.5 ± 11.7 | 1903.8 ± 10.4 | <0.001 |
| Sleep duration (h/day) | 6.8 ± 0.0 | 6.8 ± 0.0 | 6.9 ± 0.0 | 0.002 |
| Smoking (%) | <0.001 | |||
| Never | 52.1 (0.7) | 60.2 (0.6) | 60.2 (0.5) | |
| Past | 22.3 (0.6) | 19.8 (0.5) | 18.6 (0.5) | |
| Current | 25.6 (0.7) | 20.0 (0.5) | 21.3 (0.5) | |
| Alcohol (AUDIT score) | 6.4 ± 0.1 | 5.3 ± 0.1 | 5.2 ± 0.1 | <0.001 |
| Education (years) | <0.001 | |||
| ≤6 | 15.1 (0.5) | 17.7 (0.5) | 22.9 (0.5) | |
| 7–9 | 10.8 (0.4) | 9.0 (0.3) | 10.6 (0.4) | |
| 10–12 | 44.1 (0.8) | 37.2 (0.7) | 35.2 (0.6) | |
| >12 | 30.0 (0.8) | 36.1 (0.7) | 31.3 (0.7) | |
| Diabetes mellitus (%) | 7.4 (0.4) | 8.8 (0.4) | 9.6 (0.3) | <0.001 |
| Cardiovascular disease (%) | 2.6 (0.2) | 3.5 (0.2) | 3.7 (0.2) | <0.001 |
| Hypertension (%) | 24.4 (0.6) | 24.5 (0.5) | 27.0 (0.5) | <0.001 |
| Arthritis (%) | 8.9 (0.4) | 10.1 (0.3) | 12.1 (0.4) | <0.001 |
| NAFLD (%) | 21.6 (0.6) | 21.7 (0.5) | 23.4 (0.5) | 0.016 |
| Lean NAFLD (%) | 2.7 (0.2) | 3.9 (0.2) | 4.1 (0.2) | <0.001 |
| ALT (IU/L) | 21.8 ± 0.3 | 21.0 ± 0.2 | 21.8 ± 0.2 | 0.022 |
| AST (IU/L) | 22.2 ± 0.2 | 21.1 ± 0.1 | 21.6 ± 0.1 | <0.001 |
Values are the weighted means ± SE or weighted percentage (SE), as appropriate. * p values by analysis of variance for continuous variables and the Chi square test for categorical variables. HEPA, health-enhancing physical activity; BMI, body mass index; AUDIT, Alcohol Use Disorders Identification Test; NAFLD, non-alcoholic fatty liver disease; ALT: alanine aminotransferase, AST: aspartate aminotransferase.
Characteristics of participants by the presence of NAFLD (n = 32,391).
| No NAFLD | NAFLD | ||
|---|---|---|---|
| Age (years) | 45.4 ± 0.2 | 45.9 ± 0.2 | 0.032 |
| Male sex (%) | 44.5 (0.4) | 52.9 (0.8) | <0.001 |
| BMI (kg/m2) | 22.4 ± 0.0 | 27.7 ± 0.1 | <0.001 |
| Central obesity (%) | 11.0 (0.3) | 63.9 (0.8) | <0.001 |
| Total calorie intake (kcal/day) | 1961.6 ± 8.2 | 2001.7 ± 16.0 | 0.018 |
| Sleep duration (h/day) | 6.9 ± 0.0 | 6.8 ± 0.0 | 0.001 |
| Smoking (%) | <0.001 | ||
| Non | 59.4 (0.4) | 53.2 (0.8) | |
| Ex | 19.9 (0.3) | 20.3 (0.6) | |
| Current | 20.7 (0.4) | 26.6 (0.7) | |
| Alcohol (AUDIT score) | 5.5 ± 0.0 | 5.7 ± 0.1 | 0.113 |
| Education (years) | <0.001 | ||
| ≤6 | 18.5 (0.4) | 21.2 (0.6) | |
| 7–9 | 9.9 (0.3) | 11.0 (0.5) | |
| 10–12 | 38.4 (0.5) | 37.4 (0.8) | |
| >12 | 33.3 (0.5) | 30.4 (0.9) | |
| Diabetes mellitus (%) | 5.3 (0.2) | 20.7 (0.6) | <0.001 |
| Cardiovascular disease (%) | 3.1 (0.1) | 4.1 (0.1) | <0.001 |
| Hypertension (%) | 21.7 (0.4) | 38.4 (0.8) | <0.001 |
| Arthritis (%) | 9.7 (0.2) | 13.6 (0.5) | <0.001 |
| ALT (IU/L) | 17.2 ± 0.1 | 36.5 ± 0.5 | <0.001 |
| AST (IU/L) | 20.5 ± 0.1 | 25.5 ± 0.2 | <0.001 |
| Physical activity level (%) | 0.016 | ||
| HEPA active | 26.5 (0.4) | 25.3 (0.7) | |
| Minimally active | 34.5 (0.4) | 33.2 (0.7) | |
| Inactive | 39.0 (0.5) | 41.5 (0.8) |
Values are the weighted means ± SE or weighted percentage (SE), as appropriate. * p values by Student’s t-tests for continuous variables and the Chi square test for categorical variables. NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; AUDIT, Alcohol Use Disorders Identification Test; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HEPA, health-enhancing physical activity; MET, metabolic equivalent.
Adjusted OR for the independent association of physical activity with NAFLD.
| Inactive | Minimally Active | HEPA Active | ||
|---|---|---|---|---|
| NAFLD (vs. No NAFLD, | ||||
| Model 1 | 1.0 | 0.9 (0.8–0.97) | 0.9 (0.8–0.9) | 0.001 |
| Model 2 | 1.0 | 0.9 (0.8–1.03) | 0.7 (0.6–0.7) | <0.001 |
| Model 3 | 1.0 | 0.9 (0.8–1.04) | 0.7 (0.6–0.8) | <0.001 |
| Model 4 | 1.0 | 0.9 (0.8–1.03) | 0.7 (0.6–0.8) | <0.001 |
| Model 5 | 1.0 | 0.9 (0.8–1.02) | 0.7 (0.6–0.8) | <0.001 |
| Lean NAFLD (vs. Lean control subjects without NAFLD, | ||||
| Model 1 | 1.0 | 0.9 (0.8–1.1) | 0.6 (0.5–0.7) | <0.001 |
| Model 2 | 1.0 | 0.9 (0.7–1.1) | 0.5 (0.4–0.6) | <0.001 |
| Model 3 | 1.0 | 0.8 (0.7–0.98) | 0.5 (0.4–0.6) | <0.001 |
| Model 4 | 1.0 | 0.8 (0.6–0.97) | 0.5 (0.4–0.7) | <0.001 |
| Model 5 | 1.0 | 0.8 (0.6–0.98) | 0.5 (0.4–0.7) | <0.001 |
Values are the OR (95% CI). * p values by complex-samples logistic regression model. Model 1, adjusted for age and sex. Model 2, adjusted for model 1 plus BMI. Model 3, adjusted for model 2 plus total calorie intake, sleep duration, smoking, alcohol, education level. Model 4, adjusted for model 3 plus diabetes mellitus, cardiovascular disease, hypertension, arthritis. Model 5, adjusted for model 4 plus central obesity. OR, odds ratio; NAFLD, non-alcoholic fatty liver disease; HEPA, health-enhancing physical activity; BMI, body mass index.
Figure 2Adjusted weighted means of ALT (A) and AST (B) by the physical activity level among participants with NAFLD (n = 6968). Values are adjusted for age, sex, body mass index, central obesity, total calorie intake, sleep duration, smoking, alcohol, education level, diabetes mellitus, cardiovascular disease, hypertension, and arthritis. p values by complex-samples general linear models. ALT, alanine aminotransferase; HEPA, health-enhancing physical activity; AST, aspartate aminotransferase.
Adjusted OR for the independent association of physical activity with abnormal levels * of ALT and AST among participants with NAFLD (n = 6968).
| Inactive | Minimally Active | HEPA Active | ||
|---|---|---|---|---|
| Abnormal ALT | ||||
| Model 1 | 1.0 | 1.0 (0.8–1.1) | 0.8 (0.7–0.9) | 0.013 |
| Model 2 | 1.0 | 1.0 (0.8–1.1) | 0.8 (0.7–0.9) | 0.020 |
| Model 3 | 1.0 | 1.0 (0.8–1.1) | 0.8 (0.6–0.9) | 0.007 |
| Model 4 | 1.0 | 1.0 (0.8–1.2) | 0.8 (0.6–0.9) | 0.007 |
| Model 5 | 1.0 | 1.0 (0.8–1.1) | 0.8 (0.6–0.9) | 0.006 |
| Abnormal AST | ||||
| Model 1 | 1.0 | 0.9 (0.8–1.1) | 0.9 (0.8–1.1) | 0.621 |
| Model 2 | 1.0 | 0.9 (0.8–1.1) | 0.9 (0.8–1.1) | 0.652 |
| Model 3 | 1.0 | 0.9 (0.8–1.1) | 0.9 (0.7–1.1) | 0.409 |
| Model 4 | 1.0 | 0.9 (0.8–1.1) | 0.9 (0.7–1.1) | 0.451 |
| Model 5 | 1.0 | 0.9 (0.8–1.1) | 0.9 (0.7–1.1) | 0.427 |
Values are the OR (95% CI). * Defined as >34 IU/L in men or >24 IU/L in women for ALT and >32 IU/L in men or >26 IU/L in women for AST. † p values by complex-samples logistic regression model. Model 1 adjusted for age and sex. Model 2, adjusted for model 1 plus BMI. Model 3, adjusted for model 2 plus total calorie intake, sleep duration, smoking, alcohol, education level. Model 4, adjusted for model 3 plus diabetes mellitus, cardiovascular disease, hypertension, arthritis. Model 5, adjusted for model 4 plus central obesity. OR, odds ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NAFLD, non-alcoholic fatty liver disease; HEPA, health-enhancing physical activity; BMI, body mass index.